CVE-2022-45611

Exploitation

Assessed, none found. CISA's assessment recorded neither public exploit code nor evidence of exploitation when it was made.

SSVC decision

• ExploitationnoneCISA recorded no public exploit code and no evidence of exploitation.
• AutomatableyesAn attacker can reliably automate reconnaissance through exploitation, so this scales.
• Technical ImpacttotalSuccessful exploitation gives total control of the vulnerable component.

CISA publishes the decision points, not a final SSVC decision. The decision also depends on mission and well-being impact, which is a property of your deployment rather than of the vulnerability.

EPSS probability

1.17% probability of exploitation activity in the next 30 days.

EPSS percentile

Equal to or higher than the score of 67.5% of scored records. A rank, not a probability.

NVD base score

9.8 (CVSS v3.x), scored by the NVD independently of the CNA.

NVD CVSS vector

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

NVD analysis status

Modified. NVD last modified this record on 2026-06-17.

Red Hat severity

No Red Hat rating. Red Hat rates the CVEs that affect its products.

Exploit-prediction scores from FIRST. Independent scoring and analysis status from the NVD. Vendor severity from Red Hat. Exploitation assessment and catalog membership from CISA.

Published

2023-08-22 00:00Z3 YR AGO

Last updated

2024-11-27 14:25Z1 YR AGO

Reserved

2022-11-21

Assigning CNA

mitre

Record state

PUBLISHED

Severity

Not rated by the issuing CNA

CNA CVSS vector

Not published by the issuing CNA

Weaknesses

• CWE-522Insufficiently Protected CredentialsClass

Data version

5.1

Document digest

23105109b483d408fbd44cd28dce3f2a8ebb08a6fb7b9a5a6910e8d886a10a4a

• www.fresenius-kabi.comhttps://www.fresenius-kabi.com/de-at/produkte/pharmahelp-compounder
• www.fresenius.comhttps://www.fresenius.com/sites/default/files/2023-11/Fresenius%20-%20CVE-2022-45611.pdf
• www.fresenius.comhttps://www.fresenius.com/sites/default/files/2023-12/Fresenius%20-%20CVE-2022-45611.pdf